| Name | Title | Contact Details |
|---|
We are Körber – an international technology group with more than 12,000 employees at over 100 locations worldwide and a common goal: We turn entrepreneurial thinking into customer success and shape the technological change. In the Business Areas Digital, Pharma, Supply Chain, and Technologies, we offer products, solutions and services that inspire. We act fast to customer needs, we execute ideas seamlessly, and with our innovations we create added value for customers. In doing so, we are increasingly building on ecosystems that solve the challenges of today and tomorrow. Körber AG is the holding company of the Körber Group.
Midland States Bank is a community-based financial institution with over a century of history. As a subsidiary of Midland States Bancorp, Inc., headquartered in Effingham, Illinois, the bank is dedicated to supporting local businesses and residents. The bank offers a wide range of financial services, including commercial banking tailored for local businesses, wealth management with a focus on financial planning and investment services, and personal banking solutions that cater to individual needs. Midland States Bank emphasizes a personalized approach, aiming to be a supportive partner for customers during important life events. With a commitment to teamwork and community support, Midland States Bank promotes sustainable practices and social responsibility through its Environmental, Social, and Governance (ESG) initiatives. The bank continues to evolve under the leadership of CEO Leon J. Holschbach, focusing on enhancing profitability and competitiveness in the financial sector.
FifthWall Solutions is a top-rated cyber insurance partner that works with 1,500+ MSPs and their clients, accessing 45+ carriers to offer the best rates and coverage options. FifthWall also educates and equips MSPs to navigate the cyber insurance process for their clients and leverage their stack along the way. Interested in partnering with FifthWall Solutions? Message us at info@fifthwallsolutions.com or call us at 844.719.0981.
Veterinary United is a Michigan-based company that operates a network of 22 veterinary hospitals, boarding, and daycare centers primarily in Southeastern Michigan. Founded 27 years ago by Dr. Thomas Bankstahl and his wife Julie, the company has grown to employ approximately 276 people and generate annual revenues of around $40.5 million. Its mission is to empower veterinary practices to provide exceptional care through comprehensive support and resources. The company offers full veterinary healthcare services, including medical care, boarding, and daycare for pets. Veterinary United enhances its practices with advanced technology, such as a unified, cloud-based practice management system, which streamlines operations and improves client and patient experiences. Additionally, it provides extensive business support services, including IT, marketing, and professional development, allowing practices to focus on clinical care while promoting sustainable growth. Veterinary United fosters a supportive work culture that emphasizes career development and work-life balance. New veterinary graduates receive tailored mentorship, and all employees enjoy competitive salaries and benefits. The company is dedicated to delivering high-quality pet care while supporting its network of hospitals and veterinary professionals.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.